Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis -- Derry and Loke 321 (7270): 1183 Data Supplement - Further table, figure and references -- BMJ

Table 1 Additional details on the included studies

Study	Year	Age (mean or range, years)	Male (%)	Definition of haemorrhage	Loss to follow up (%)	Concealment of allocation
Diener et al^{w1 w2}	1996	66	58	Haematemesis and/or melaena	<1	Adequate
Hansson et al^w3	1998	61.5	53	Gastrointestinal bleed	2.6	Adequate
Petersen et al^w4	1989	75	54	Gastrointestinal bleed	Unclear	Adequate
SALT^w5	1991	67	66	Gastrointestinal bleed	<1	Adequate
TPT^w6	1998	45-69	100	Gastrointestinal bleed	1	Adequate
Wallentin^w7	1991	58	100	Gastrointestinal bleed	0	Unclear
Silagy et al^w8	1993	73	49	Haematemesis and/or melaena	0	Unclear
USPHS^w9	1989	40-84	100	Haematemesis and/or melaena	Unclear	Adequate
EAFT^w10	1993	73	55	Gastrointestinal bleed	<1	Adequate
Elwood et al^w11	1974	55	100	Gastrointestinal haemorrhage	Unclear	Unclear
UKTIA^w12	1991	60	73	Gastrointestinal bleed	0	Adequate
Gavaghan et al^w13	1991	56	85	Gastrointestinal bleed	<1	Unclear
Olivotto et al^w14	1996	53	0	Gastrointestinal bleed	Unclear	Unclear
Elwood et al^w15	1979	56	85	Gastrointestinal bleed	0	Unclear
CDPA^w16	1976	60%>55	100	Haematemesis and/or melaena	Unclear	Unclear
PARIS^w17	1980	30-74	81	Gastrointestinal bleed	6.7	Adequate
Hess et al^w18	1985	62	80	Gastrointestinal bleed	0	Unclear
AMIS^w19	1980	54	89	Haematemesis and/or melaena	<1	Unclear
Breddin et al^w20	1980	40-70	79	Gastrointestinal haemorrhage	9.6	Adequate
CCSG^w21	1978	Unclear	67	Haematemesis and/or melaena	<1	Adequate
Fields et al^w22	1977	>45	66	Gastrointestinal bleed	5	Adequate
Fields et al^w23	1978	>45	74	Gastrointestinal haemorrhage	Unclear	Adequate
Britton^w24	1987	68	62	Gastrointestinal haemorrhage	Unclear	Adequate
Ehresman et al^w25	1977	59	94	Gastrointestinal bleed	11.2	Unclear

SALT=Swedish aspirin low dose trial; TPT=thrombosis prevention trial; USPHS=US physicians health study; EAFT=European atrial fibrillation trial; UK TIA=UK transient ischaemic attack aspirin trial; CDPA=coronary drug project aspirin study; PARIS=persantine-aspirin reinfarction study; AMIS=aspirin myocardial infarction study; CCSG=Canadian Cooperative Study Group.

Figure 1

Funnel plot of Peto odds ratio against the inverse standard error

References

w1 Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European stroke prevention study. 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.

w2 Diener HC, Forbes C, Riekkinen PJ, Sivenius J, Smets P, Lowenthal A. European stroke prevention study. 2: Efficacy and safety data: the ESPS 2 group. J Neurol Sci 1997;151(suppl):S1-61.

w3 Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.

w4 Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-9.

w5 SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-9.

w6 Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998;351:233-41.

w7 Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991;18:1587-93.

w8 Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993;54:84-9.

w9 Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989;321:129.

w10 EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.

w11 Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1974;1:436-40.

w12 Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:1044-54.

w13 Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 1991;83:1526-33.

w14 Olivotto IA, Kim-Sing C, Bajdik CD, Trevisan CH, Ludgate CM, Weir LM, et al. Effect of acetylsalicylic acid on radiation and cosmetic results after conservative surgery for early breast cancer: a randomized trial. Radiother Oncol 1996;41:1-6.

w15 Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet 1979;2:1313-5.

w16 Coronary Drug Project Research Group. Aspirin in coronary heart disease. J Chronic Dis 1976;29:625-42.

w17 Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation 1980;62:449-61.

w18 Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985;1:415-9.

w19 Aspirin Myocardial Infarction Study Research Group. The aspirin myocardial infarction study: final results. Circulation 1980;62(6, part 2):V79-84.

w20 Breddin K, Loew D, Lechner K, Uberla K, Walter E. Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis 1980;9:325-44.

w21 Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53-9.

w22 Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Stroke 1977;8:301-14.

w23 Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Part II: surgical group. Stroke 1978;9:309-19.

w24 Britton M, Helmers C, Samuelsson K. High-dose acetylsalicylic acid after cerebral infarction. A Swedish cooperative study. Stroke 1987;18:325-34.

w25 Ehresmann U, Alemany J, Loew D. Prophylaxe von Rezidivverschlussen nach Revaskularisations-eingriffen mit Acetylsalicylsaure. Ergebnisse einer doppeltblinden Langzeitstudie. Med Welt 1977;28:1157-62.